Heat Biologics Says In 8K It Has Cash, Cash Equivalents And Short-Term Investments Of $35.5M As Of June 1; Says It Believes It Has Sufficient Cash To Fund Operations And Current And Planned Clinical Activities Into Q1 Of 2022
Benzinga Newsdesk